MichaelaLTsaiMD

Oncology • Seattle, WA

Medical Director of Breast Oncology Deputy Director of Clinical Operations

Join to view full profile

Dr. Tsai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tsai's full profile

Already have an account?

Office
1221 Madison St
Suite 500
Seattle, WA 98104
Phone+1 206-386-2828

Fax+1 206-386-3782

Summary

Dr. Michaela Tsai is a medical oncologist and hematologist. She is the medical director of the breast oncology program at the Swedish Cancer Institute in Seattle, WA. She also directs the breast clinical research program, the survivorship program, and the cancer genetics program.

Education & Training

Harvard Medical SchoolClass of 1998
Duke UniversityBS, Chemistry and Religion, Summa Cum Laude, 1990 - 1994

Certifications & Licensure

WA State Medical License 2021 - 2025
AK State Medical License 2023 - 2024
MN State Medical License 2000 - 2021
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

38 citations
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amer M. Zeidan, Maya Ridinger, Tara L. Lin, Pamela S. Becker, Gary J. Schiller
Clinical Cancer Research. 2020-09-30
59 citations
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira
Annals of Oncology. 2021-09-01
51 citations
Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)
Debra L. Barton, Jeff A. Sloan, Lynne T. Shuster, Paula Gill, Patricia C. Griffin
Supportive Care in Cancer. 2018-02-01

Abstracts/Posters

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Michaela L. Tsai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Mult...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

70-Gene Signature Impacts Treatment Decisions in Breast CAOctober 29th, 2017
New Data Shows Agendia’s MammaPrint® Can Prevent Under and over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence ScoreJune 7th, 2016
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to Their Medical Advisory BoardJune 1st, 2016
Join now to see all